Literature DB >> 24900718

4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors.

Muriel Billamboz1, Virginie Suchaud1, Fabrice Bailly1, Cedric Lion1, Jonas Demeulemeester2, Christina Calmels3, Marie-Line Andréola3, Frauke Christ2, Zeger Debyser2, Philippe Cotelle1.   

Abstract

A series of 2-hydroxy-1,3-dioxoisoquinoline-4-carboxamides featuring an N-hydroxyimide chelating functionality was evaluated for their inhibitory properties against human immunodeficiency virus type 1 integrase (HIV-1 IN). Several derivatives displayed low nanomolar IC50 values comparable to that of the clinically used raltegravir. A marked effect of one compound on both primary IN-catalyzed reactions, strand transfer (ST), and 3' processing (3'-P), emphasizes a novel IN inhibition mechanism establishing it as a potential new generation IN inhibitor. Substitution of the 2-hydroxyisoquinoline-1,3-dione scaffold at position 4 by carboxamido chains was beneficial for antiviral activity since reproducible low micromolar anti-HIV activities were obtained for the first time within this scaffold.

Entities:  

Keywords:  2-hydroxy-1,3-dioxoisoquinoline-4-carboxamide; 3′ processing; HIV; antiretroviral; integrase

Year:  2013        PMID: 24900718      PMCID: PMC4027527          DOI: 10.1021/ml400009t

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

1.  2-hydroxyisoquinoline-1,3(2H,4H)-diones as inhibitors of HIV-1 integrase and reverse transcriptase RNase H domain: influence of the alkylation of position 4.

Authors:  Muriel Billamboz; Fabrice Bailly; Cédric Lion; Christina Calmels; Marie-Line Andréola; Myriam Witvrouw; Frauke Christ; Zeger Debyser; Laura De Luca; Alba Chimirri; Philippe Cotelle
Journal:  Eur J Med Chem       Date:  2010-11-27       Impact factor: 6.514

2.  The elvitegravir Quad pill: the first once-daily dual-target anti-HIV tablet.

Authors:  Christophe Marchand
Journal:  Expert Opin Investig Drugs       Date:  2012-05-10       Impact factor: 6.206

3.  MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

Authors:  Mathieu Métifiot; Barry Johnson; Steven Smith; Xue Zhi Zhao; Christophe Marchand; Terrence Burke; Stephen Hughes; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

4.  Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

Authors:  Filippo Canducci; Elisa R Ceresola; Enzo Boeri; Vincenzo Spagnuolo; Francesca Cossarini; Antonella Castagna; Adriano Lazzarin; Massimo Clementi
Journal:  J Infect Dis       Date:  2011-10-07       Impact factor: 5.226

5.  Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function.

Authors:  Muriel Billamboz; Fabrice Bailly; Cédric Lion; Nadia Touati; Hervé Vezin; Christina Calmels; Marie-Line Andréola; Frauke Christ; Zeger Debyser; Philippe Cotelle
Journal:  J Med Chem       Date:  2011-03-02       Impact factor: 7.446

6.  Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors.

Authors:  Laith Q Al-Mawsawi; Raveendra Dayam; Laleh Taheri; Myriam Witvrouw; Zeger Debyser; Nouri Neamati
Journal:  Bioorg Med Chem Lett       Date:  2007-10-10       Impact factor: 2.823

7.  Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain.

Authors:  Muriel Billamboz; Fabrice Bailly; Maria Letizia Barreca; Laura De Luca; Jean-François Mouscadet; Christina Calmels; Marie-Line Andréola; Myriam Witvrouw; Frauke Christ; Zeger Debyser; Philippe Cotelle
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

8.  Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro.

Authors:  Eric Deprez; Sophie Barbe; Macieij Kolaski; Hervé Leh; Fatima Zouhiri; Christian Auclair; Jean-Claude Brochon; Marc Le Bret; Jean-François Mouscadet
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

Review 9.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy.

Authors:  Damian J McColl; Xiaowu Chen
Journal:  Antiviral Res       Date:  2009-11-17       Impact factor: 5.970

Review 10.  Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors.

Authors:  Erik Serrao; Srinivas Odde; Kavya Ramkumar; Nouri Neamati
Journal:  Retrovirology       Date:  2009-03-05       Impact factor: 4.602

View more
  8 in total

1.  Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity.

Authors:  Catherine W Cai; Elena Lomonosova; Eileen A Moran; Xiaohong Cheng; Kunjan B Patel; Fabrice Bailly; Philippe Cotelle; Marvin J Meyers; John E Tavis
Journal:  Antiviral Res       Date:  2014-05-20       Impact factor: 5.970

2.  Double-Winged 3-Hydroxypyrimidine-2,4-diones: Potent and Selective Inhibition against HIV-1 RNase H with Significant Antiviral Activity.

Authors:  Sanjeev Kumar V Vernekar; Jing Tang; Bulan Wu; Andrew D Huber; Mary C Casey; Nataliya Myshakina; Daniel J Wilson; Jayakanth Kankanala; Karen A Kirby; Michael A Parniak; Stefan G Sarafianos; Zhengqiang Wang
Journal:  J Med Chem       Date:  2017-05-31       Impact factor: 7.446

3.  Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase.

Authors:  Jing Tang; Sanjeev Kumar V Vernekar; Yue-Lei Chen; Lena Miller; Andrew D Huber; Nataliya Myshakina; Stefan G Sarafianos; Michael A Parniak; Zhengqiang Wang
Journal:  Eur J Med Chem       Date:  2017-03-29       Impact factor: 6.514

4.  Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles.

Authors:  Tiffany C Edwards; Elena Lomonosova; Jenny A Patel; Qilan Li; Juan A Villa; Ankit K Gupta; Lynda A Morrison; Fabrice Bailly; Philippe Cotelle; Erofili Giannakopoulou; Grigoris Zoidis; John E Tavis
Journal:  Antiviral Res       Date:  2017-04-25       Impact factor: 5.970

5.  Design, synthesis, biochemical, and antiviral evaluations of C6 benzyl and C6 biarylmethyl substituted 2-hydroxylisoquinoline-1,3-diones: dual inhibition against HIV reverse transcriptase-associated RNase H and polymerase with antiviral activities.

Authors:  Sanjeev Kumar V Vernekar; Zheng Liu; Eva Nagy; Lena Miller; Karen A Kirby; Daniel J Wilson; Jayakanth Kankanala; Stefan G Sarafianos; Michael A Parniak; Zhengqiang Wang
Journal:  J Med Chem       Date:  2014-12-30       Impact factor: 7.446

6.  Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

Authors:  Xue Zhi Zhao; Steven J Smith; Mathieu Métifiot; Barry C Johnson; Christophe Marchand; Yves Pommier; Stephen H Hughes; Terrence R Burke
Journal:  J Med Chem       Date:  2014-02-10       Impact factor: 7.446

Review 7.  Progress in HIV-1 Integrase Inhibitors: A Review of their Chemical Structure Diversity.

Authors:  Zahra Hajimahdi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

Review 8.  In search of therapeutic candidates for HIV/AIDS: rational approaches, design strategies, structure-activity relationship and mechanistic insights.

Authors:  Dinesh Kumar; Pooja Sharma; Ramandeep Kaur; Maloba M M Lobe; Girish K Gupta; Fidele Ntie-Kang
Journal:  RSC Adv       Date:  2021-05-18       Impact factor: 4.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.